|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. American Dental Association, 65 American Diabetes Association, 46, 135 American Dietetic Association (ADA), 46, 65 American Heart Association (AHA), 20, 46, 83, 85, 103, 135, 136, 139, 186 American Medical Association (AMA), 20, 27, 187 American Organization of Nurse Executives, 65 American Society for Therapeutic Radiology and Oncology, 134 American Society of Clinical Oncology (ASCO), 46, 65, 85, 134 American Urological Association, 134 Appraisal of Guidelines Research and Evaluation (AGREE) Instrument, 136-137, 155, 231-232 AQA Alliance, 48 Australia, national programs, 124, 160, 161, 162, 163 Autologous bone marrow transplant, 64-65, 68 B Back pain, 68, 69, 70, 95, 96, 139, 157 Benchmarks of appropriate care, 39, 40, 43 Bevacizumab (Avastin®) for age-related macular degeneration, 20, 92, 183 Bias. See also Conflicts of interest attrition, 98 detection/ascertainment, 98 information, 98 intellectual, 75, 129-130, 143, 144, 145, 158 minimizing, 91, 97-98, 129-132, 139, 142-146, 157, 159 performance, 98 selection, 98 statistical, 8 Blue Cross and Blue Shield Association (BCBSA), 28 Technology Evaluation Center (TEC), 20, 26, 43, 44, 59, 60, 62, 67, 69-70, 71, 84, 85, 189 Breast cancer, 64-65, 68, 69, 72, 77, 92, 95, 96, 137 Burden-of-disease criterion, 6, 11, 13, 71-72, 73, 74, 76, 172-173, 197 C Canada, national program, 28, 71, 102, 123, 124, 160, 161, 162, 163, 215 Canadian Agency for Drugs and Technologies in Health (CADTH), 71, 162, 215 Canadian Task Force on the Periodic Health Examination, 28, 123 Cardiovascular care, 46, 51, 68, 82, 95, 96, 103, 135, 186 Case-control studies, 4, 23, 24, 91, 92, 223 Case series, 4, 23, 24, 91, 92, 102, 103 Center for Biologics Evaluation and Research, 42 Center for Devices and Radiological Health, 42 Center for Drug Evaluation and Research (CDER), 42 Center for Medical Effectiveness Research, 27 Centers for Disease Control and Prevention, 42, 65, 83-84, 206, 217 Centers for Medicare & Medicaid Services (CMS), 64, 65, 188, 21 coverage determinations, 51, 59-61, 93, 94, 95 expenditures on health services, 37, 38, 39, 50-51, 163 Medicare Coverage Advisory Committee (MCAC), 27, 45 Medicare Evidence Development and Coverage Advisory Committee (MedCAC), 27, 45, 59-60, 62, 71, 75, 83, 84 regional differences in spending, 38, 39 utilization of evidence assessments, 26, 27, 28, 44, 45, 83, 84
|
|
|||||||||||||||
